表紙:分子診断検査の世界市場:第10版 (NGS、PCR、NAAT、ISH、TMA、その他)
市場調査レポート
商品コード
1018629

分子診断検査の世界市場:第10版 (NGS、PCR、NAAT、ISH、TMA、その他)

The World Market for Molecular Diagnostics Tests, 10th Edition (NGS, PCR, NAAT, ISH, TMA, Other)

出版日: | 発行: Kalorama Information | ページ情報: 英文 337 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
分子診断検査の世界市場:第10版 (NGS、PCR、NAAT、ISH、TMA、その他)
出版日: 2021年06月17日
発行: Kalorama Information
ページ情報: 英文 337 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

分子診断は、急速に進化しているダイナミックな分野であり、体外診断用医薬品 (IVD) 市場の中で最も成長している分野です。分子診断は、抗菌剤耐性 (AMR) 感染症の早期発見による治療方針の決定、様々ながん治療法の適合性評価を支援するコンパニオン診断、HIVや精神疾患、血液希釈剤の薬物動態や患者の代謝、がんの予後や治療、臓器適合、血液の安全性、潜在疾患や新生児の診断など、医療のあらゆる側面に関わる臨床医学の不可欠なツールとなっています。

当レポートでは、世界の分子診断検査の市場について分析し、昨今の技術開発・普及の動きや、全体的な市場規模の動向見通し (2021年~2026年)、用途別・技術セグメント別・地域別の詳細動向、主要企業のプロファイルと競合情勢、といった情報を取りまとめてお届けいたします。

目次

第1章 エグゼクティブサマリー

  • 市場の情勢・展望を左右する新たな動向
  • 標本即時診断 (Sample to Results)/ポイントオブケア (PoC) システムによる、分子検査の民主化
  • 従来型IVD (体外診断) セグメントに対する分子診断の影響
  • 分子診断のための償還環境 (米国・欧州・カナダ・日本・中国・インド)
  • 正の償還決定を受けた分子検査の例
  • 分子診断の臨床的有用性
  • LDT (臨床検査開発テスト) の規制状況
  • 高度なバイオインフォマティクス/その他のITプラットフォームの影響
  • 世界の分子診断市場
  • 技術別の成長動向:NGSの約束、既存セグメントの強さ
  • 地域別の分子診断市場 (北米・欧州・アジア太平洋)

第2章 技術セグメント別の市場

  • 核酸増幅検査 (NAAT) 技術
  • 臨床NAAT診断市場の市場動向
  • 分子検査の分散化
  • 自動化・一元化による、既存検査のコモディティ化
  • NAATの革新:新しいバイオマーカー、高スループット、デジタルPCR
  • リアルタイムPCR (qPCR)
  • 等温核酸増幅技術 (iNAAT)
  • マイクロアレイ
  • マイクロアレイ検査の市場動向
  • 分子免疫血液検査と分子血液型検査
  • マイクロアレイの代替としての、サスペンションアレイとその他の検査
  • インサイチュハイブリダイゼーション (ISH)
  • ISHの市場動向
  • デジタルパソロジーのアルゴリズム
  • 臨床RNA ISH
  • 代替のISHプローブおよび試薬
  • シーケンシング
  • 臨床シーケンシングの市場動向
  • 小型化・速度・コストの改善
  • 臨床シーケンシングにおけるインフォマティクス・ソリューションの進化
  • サンプル調製と品質管理
  • NGSのリキッドバイオプシー
  • 全エクソームシーケンス (WES)
  • メチル化
  • 事業協力と企業買収:NGSの市場情勢の急速な変化
  • 中国国内のNGS需要の急成長
  • アジア太平洋のNGS市場の見通し

第3章 感染症向け分子診断の市場

  • 感染症診向け分子POC分子検査の展望
  • 世界市場の分析
  • CT/NG (クラミジア・トラコマチス/淋菌)、HPV (ヒトパピローマウイルス)、婦人科疾患
  • 肝炎
  • HIV
  • 院内感染 (HAI)
  • 呼吸器疾患
  • マイコバクテリア/結核

第4章 血液スクリーニング向け分子診断の市場

  • 先進国市場における輸血の減少
  • 発展途上国における需要の高まり
  • 新しい感染症の脅威とアッセイの導入
  • 血液スクリーニング向け核酸検査の市場
  • 地域別の血液検査市場

第5章 分子組織・細胞診断の市場

  • 分子組織診断セグメントの市場動向
  • CISH、信号検出、試薬化学の革新
  • 組織診断の自動化

第6章 がん分子診断の市場

  • がん分子診断の市場動向
  • がん診断における超並列シーケンス
  • 遺伝性がん診断における分子診断の役割
  • 薬物と遺伝子の一致を特定するためのバイオマーカー予測検査
  • リキッドバイオプシーベースの非侵襲がん分子診断
  • 原発不明がん (CUP) の分子診断
  • 分子がん診断の進化と現状
  • 世界のがん分子診断市場
  • 北米のがん分子診断市場
  • 欧州のがん分子診断市場
  • アジア太平洋のがん分子診断市場
  • 日本
  • 中国
  • インド
  • ASEAN諸国

第7章 分子移植診断の市場

  • 高度DNA検査プラットフォームへの技術シフト
  • 投資拡大、イノベーション、市場の統合、その他の動向
  • 世界の分子移植診断市場

第8章 遺伝性疾患分子診断の市場

  • 静脈血栓症と凝固マーカー
  • 非侵襲的出生前検査 (NIPT)
  • 自閉症
  • アルツハイマー病
  • 循環器疾患
  • 精神障害

第9章 企業プロファイル

  • Abbott Diagnostics
  • Advanced Cell Diagnostics (Biotechne)
  • Agilent Technologies
  • Amoy Diagnostics
  • Applied Spectral Imaging
  • Becton, Dickinson & Co. (BD)
  • Beijing Genomics Institute (BGI)
  • Berry Genomics
  • bioMérieux
  • Bio-Rad Laboratories
  • CareDx, Inc.
  • Danaher (Cepheid and Leica Biosystems)
  • Cepheid
  • Leica Biosystems
  • Eiken Chemical
  • GenMark Diagnostics
  • Genotypic Technology Pvt. Ltd.
  • Grifols, S. A
  • Illumina
  • Immucor, Inc.
  • Meridian Bioscience Inc
  • Molbio Diagnostics Pvt. Ltd.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics
目次
Product Code: 21-028

Molecular diagnostics is a fast evolving and dynamic field and is the fastest growing segment within the in vitro diagnostics (IVD) market. It has become an indispensable tool in clinical medicine that touches all aspects of healthcare including treatment decisions in terms of identifying antimicrobial resistant (AMR) infections at the earliest, companion diagnostics assisting in the evaluation of suitability of various cancer treatment options, pharmacokinetics or patient metabolism of drugs for HIV, psychiatric conditions or blood thinners; cancer prognosis and therapy, organ matching, blood safety, and the diagnosis of latent and neonatal conditions. Kalorama's “ The World Market for Molecular Diagnostics Tests, 10th Edition (NGS, PCR, NAAT, ISH, TMA, Other) ” , examines the global market as well as markets by region, including:

  • Global Markets for Molecular Diagnostics by Application Segments (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total) ($, Million)
  • Global Markets for Molecular Diagnostics by Technology Segments (2021-2026) (PCR, iNAAT, Microarrays, ISH, NGS, Other, Total) ($, Million)
  • North American Markets for Molecular Diagnostics (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total) ($, Million)
  • European Markets for Molecular Diagnostics (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total) ($, Million)
  • Asia Pacific Markets for Molecular Diagnostics (2021-2026) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant , Inherited Diseases, Total) ($, Million)

Detection of active and latent patient infections by targeting genetic sequences specific to pathogens is the approach used in molecular infectious disease tests. Clinical molecular tests available for infectious disease testing offer a combination of high sensitivity, specificity and low turnaround time advantages.

This has powered this segment for high market growth over other major diagnostic platforms commonly used for infectious disease testing such as immunoassay and ID/AST. Molecular detection platforms are increasingly being recognized for the improved sensitivity and specificity they can offer, even though they are more expensive. The report offers global analysis of the molecular infectious disease diagnostics segment, as well as analysis of subsegments that include CT/NG, HPV, hepatitis, HIV, HAIs, respiratory diseases, and tuberculosis:

  • Global Molecular Infectious Disease Diagnostics Markets (2021-2026), By Infection (Hepatitis, HIV, HAIs/Sepsis, HPV, CT/NG, Respiratory diseases, Mycobacteria/TB, Other, Total) ($, Million)
  • Global Molecular Infectious Disease Diagnostics Markets, by Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular HPV Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular CT/NG Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Hepatitis Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular HIV Testing Markets, By Region (North America, Europe, APAC, RoW, Total) (2021-2026) ($, Million)
  • Global Molecular HAIs/Sepsis Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Respiratory Diseases Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Mycobacteria/TB Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)

As a result of concerted efforts to make blood product transfusions safer, there is an increase in antigen testing by nucleic acid test (NAT) screening to test for common pathogens. Developing countries are replacing immunoassays by molecular tests, especially for HIV, hepatitis, etc. World Molecular Diagnostics Market covers the markets for molecular blood screening diagnostics, outlining the blood testing market by geography:

  • Global Molecular Blood Screening Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)

    Molecular histology, which predominantly consists of ISH tests, captures several different areas of testing including molecular cytogenetics or study of chromosomes, related techniques for the detection of pre- and post-natal genetic disorders, cancer testing, and the detection of pathogens or pathogenic activity from tissues and blood cultures. Various sub-segments within the ISH segment of molecular histology market include FISH, CISH, Rapid ISH (RISH), etc. CISH for RNA markers is increasingly used in drug development and companion diagnostics. The report analyzes key molecular histology segments:

  • Global Molecular Histology and Cytology Diagnostics Markets by Application (2021-2026) (Cancer, Inherited diseases, Infectious/Other, Total) ($, Million)
  • Global Molecular Histology and Cytology Diagnostics Markets, by Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)
  • Global Molecular Histology Diagnostics Markets, by Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)

This report reviews the current makeup of the molecular diagnostics market in cancer, including its notable products and geographical segmentation. The report also reviews expected developments, such as technology and product introduction. The current market is largely composed of tissue-based tests, companion assays, and tests for the prognosis and diagnosis of specific cancer types. Some of the most significant developments in this field may have an impact in shaping cancer diagnostics and treatment management. The report examines the markets for molecular cancer diagnostics, outlining the global market by geography:

  • Global Molecular Cancer Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)

The molecular transplant diagnostics space is a competitive market with many companies offering PCR-based and bead-array-based test kits based on the HLA genes that have been characterized. The demand for NGS has been growing in the segment. An HLA test requires that some six genes are screened in parallel, with each displaying about 100 important (known) local variants. This requirement lends itself to technologies such as microarrays and sequencing that can screen for many targets. The report outlines the markets for molecular transplant diagnostics by geography:

  • Global Molecular Transplant Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)

The detection of single nucleotide polymorphisms (SNPs) or gene variants from tissue, blood, urine and saliva samples can be used to diagnose inherited diseases and genetic disorders as well as determine the risk of disease manifestation or progression. One of the major challenges facing molecular tests for gene based inherited diseases is getting stakeholders including payers, physicians, researchers and regulators to work together to close the gap between research and clinical applicability. World Molecular Diagnostics Market analyzes the developments in most significant markets within molecular inherited disease diagnostics and provides the following market data:

  • Global Molecular Inherited Diseases Diagnostics Markets, By Disease Segments (2021-2026) (Thrombophilia [SNP tests] & Coagulation Markers, NIPT, Others, Total) ($, Million)
  • Global Molecular Inherited Diseases Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total) ($, Million)

In addition to reviewing recent industry and market developments, as well as examining key market trends that are influencing the market landscape, the report looks at the molecular diagnostics industry players.

The following companies are profiled:

  • Abbott Diagnostics
  • Advanced Cell Diagnostics (Biotechne)
  • Agilent Technologies
  • Amoy Diagnostics
  • Applied Spectral Imaging
  • Becton, Dickinson & Co. (BD)
  • Beijing Genomics Institute (BGI)
  • Berry Genomics
  • bioMérieux
  • Bio-Rad Laboratories
  • CareDx, Inc.
  • Danaher (Cepheid and Leica Biosystems)
  • Eiken Chemical
  • GenMark Diagnostics
  • Genotypic Technology Pvt. Ltd.
  • Grifols, S. A
  • Illumina
  • Immucor, Inc.
  • Meridian Bioscience Inc
  • Molbio Diagnostics Pvt. Ltd.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics

Table of Contents

Chapter One: Executive Summary

  • Emerging Trends Influencing the Market Landscape
  • Democratization of Molecular Testing with Sample-to-Result and POC Systems
  • Impact of Molecular Diagnostics on Conventional IVD Segments
  • Reimbursement Environment for Molecular Diagnostics
  • Reimbursement Environment in the US
  • Reimbursement Environment in Europe
  • Reimbursement Environment in Canada
  • Reimbursement Environment in Japan
  • Reimbursement Environment in China
  • Reimbursement Environment in India
  • Examples of Molecular Tests that Received Positive Reimbursement Decisions
  • Clinical Utility of Molecular Diagnostics
  • Regulatory Status of Laboratory Developed Tests (LDTs)
  • Influence of Advanced Bioinformatics and other IT platforms
  • The Global Molecular Diagnostics Market
    • Table 1-1: Global Markets for Molecular Diagnostics by Application Segments (2021-2026) ($, Million) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total)
  • Growth by Technology: The Promise of NGS, Strength of Incumbent Segments
    • Table 1-2: Global Markets for Molecular Diagnostics by Technology Segments (2021-2026) ($, Million) (PCR, iNAAT, Microarrays, ISH, NGS, Other, Total)
  • Molecular Diagnostics Markets by Region
  • North American Markets for Molecular Diagnostics
    • Table 1-3: North American Markets for Molecular Diagnostics (2021-2026) ($, Million) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total)
  • European Markets for Molecular Diagnostics
    • Table 1-4: European Markets for Molecular Diagnostics (2021-2026) ($, Million) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases, Total)
  • Asia Pacific Markets for Molecular Diagnostics
    • Table 1-5: Asia Pacific Markets for Molecular Diagnostics (2021-2026) ($, Million) (Infectious Diseases, Blood Screening, Histology, Cancer Assays, Transplant , Inherited Diseases, Total)

Chapter Two: Markets by Technology Segments

  • Nucleic Acid Amplification Test (NAAT) Technologies
  • Market Trends in the Clinical NAAT Diagnostics Markets
  • Decentralization of molecular tests
  • Commoditization of established tests through automation and centralization
  • Innovation in NAAT ñ New Biomarkers, Higher Throughput, and digital PCR
    • Table 2-1: Commercially Available DNA Methylation Tests for Cancer
  • Real-Time PCR (qPCR)
  • Isothermal Nucleic Acid Amplification Technology (iNAAT)
    • Table 2-2: Selected iNAAT Methods and Commercially Available Platforms
  • Microarrays
  • Market Trends in Microarray Testing
  • Molecular Immunohematology or Molecular Blood Typing
  • Suspension Arrays and Others as Alternatives to Microarrays
    • Table 2-3: Selected Clinical Arrays Component and Microarray Systems
  • In Situ Hybridization (ISH)
    • Table 2-4: Selected Commercial In Situ Hybridization Tests
  • Market Trends in ISH
  • Digital Pathology Algorithms
  • Clinical RNA ISH
  • Alternative ISH Probes and Reagents
  • Sequencing
    • Table 2-5: Selected Clinical NGS Platforms in the Market
  • Market Trends in Clinical Sequencing
  • Improvements in Miniaturization, Speed and Cost
  • Evolving Informatics Solutions in Clinical Sequencing
  • Sample Preparation and Quality Control
  • Liquid Biopsy in NGS
  • Whole Exome Sequencing (WES)
  • Methylation
  • Collaborations and Acquisitions: NGS Market Landscape Changing Fast
    • Table 2-6: Selected Acquisitions/Collaborations in the NGS Market (2017-2021)
  • Fast Growing NGS Demand in China
  • NGS Market Outlook for APAC

Chapter Three: Markets for Molecular Infectious Disease Diagnostics

  • Table 3-1: Selected Integrated Clinical Molecular Systems in the Market for Infectious Disease Diagnostics
  • Prospects for Molecular POC Testing for Infectious Diseases Diagnostics
    • Table 3-2: Selected Molecular POC Platforms in the Market for Infectious Disease Testing
  • Market Analysis - Global
    • Table 3-3: Global Molecular Infectious Disease Diagnostics Markets (2021-2026), By Infection ($, Million) (Hepatitis, HIV, HAIs/Sepsis, HPV, CT/NG, Respiratory diseases, Mycobacteria/TB, Other, Total)
    • Table 3-4: Global Molecular Infectious Disease Diagnostics Markets, by Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)
  • CT/NG, HPV and Womenís Health
    • Table 3-5: Global Molecular HPV Testing Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)
    • Table 3-6: Global Molecular CT/NG Testing Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)
  • Hepatitis
    • Table 3-7: Global Molecular Hepatitis Testing Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)
  • HIV
    • Table 3-8: Innovations in Molecular POC Diagnostics for HIV
    • Table 3-9: Global Molecular HIV Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total)
  • Hospital-Acquired Infections (HAIs)
    • Table 3-10: Global Molecular HAIs/Sepsis Testing Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total)
  • Respiratory Diseases
    • Table 3-11: Global Molecular Respiratory Diseases Testing Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)
  • Mycobacteria/Tuberculosis
    • Table 3-12: Global Molecular Mycobacteria/TB Testing Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)

Chapter Four: Markets for Molecular Blood Screening Diagnostics

  • Declining Blood Transfusions in Developed Markets
  • Growing Demand in Developing Nations
  • New Infectious Disease Threats and Assay Introductions
  • Nucleic Acid Testing Markets for Blood Screening
  • Blood Testing Market by Geography
    • Table 4-1: Global Molecular Blood Screening Diagnostics Markets, By Region (2021-2026) (North America, Europe, APAC, RoW, Total)

Chapter Five: Markets for Molecular Histology and Cytology Diagnostics

  • Market Trends in Molecular Histology Segment
  • Innovation in CISH, Signal Detection and Reagent Chemistries
  • Histology Automation
    • Table 5-1: Global Molecular Histology and Cytology Diagnostics Markets by Application (2021-2026) ($, Million) (Cancer, Inherited diseases, Infectious/Other, Total)
    • Table 5-2: Global Molecular Histology and Cytology Diagnostics Markets, by Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)
    • Table 5-3: Global Molecular Histology Diagnostics Markets, by Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)

Chapter Six: Markets for Molecular Cancer Diagnostics

  • Market Trends in Molecular Cancer Diagnostics
  • Massively Parallel Sequencing in Cancer Diagnostics
  • Role of Molecular Diagnostics in Hereditary Cancer Diagnosis
  • Predictive Biomarker Tests for Identifying Drug-Gene Match
  • Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
    • Table 6-1: Companies Offering Liquid Biopsy-based Molecular Cancer Assays
  • Molecular Diagnosis of Cancers of Unknown Primary Site (CUP)
  • Evolution of Molecular Cancer Diagnostics and Current Status
    • Table 6-2: Selected Molecular Companion and Complementary Assays for Cancer
  • Cancer Molecular Diagnostics Markets, Global
    • Table 6-3: Global Molecular Cancer Diagnostics Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)
  • Cancer Molecular Diagnostics Markets, North America
  • Cancer Molecular Diagnostics Markets, Europe
  • Cancer Molecular Diagnostics Markets, APAC
  • Japan
  • China
    • Table 6-4: Recent Partnerships Established between Illumina and Diagnostics Companies in China
  • India
  • ASEAN

Chapter Seven: Markets for Molecular Transplant Diagnostics

  • Technological Shift to Advanced DNA Testing Platforms
  • Rising Investments, Innovation, Market Consolidation, and Other Trends
    • Table 7-1: Selected Innovations in the Field of Molecular Transplant Diagnostics
  • Molecular Transplant Diagnostics, Global
    • Table 7-2: Global Molecular Transplant Diagnostics Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)

Chapter Eight: Markets for Molecular Inherited Diseases Diagnostics

  • Thrombophilia and Coagulation Markers
  • Non-Invasive Prenatal Testing (NIPT)
  • Autism
  • Alzheimerís Disease
  • Cardiovascular Disease
  • Psychiatric Disorders
    • Table 8-1: Global Molecular Inherited Diseases Diagnostics Markets, By Disease Segments (2021-2026) ($, Million) (Thrombophilia [SNP tests] & Coagulation Markers, NIPT, Others, Total)
    • Table 8-2: Global Molecular Inherited Diseases Diagnostics Markets, By Region (2021-2026) ($, Million) (North America, Europe, APAC, RoW, Total)

Chapter Nine: Company Profiles

  • Abbott Diagnostics
  • Advanced Cell Diagnostics (Biotechne)
  • Agilent Technologies
  • Amoy Diagnostics
  • Applied Spectral Imaging
  • Becton, Dickinson & Co. (BD)
  • Beijing Genomics Institute (BGI)
  • Berry Genomics
  • bioMe¥rieux
  • Bio-Rad Laboratories
  • CareDx, Inc.
  • Danaher (Cepheid and Leica Biosystems)
  • Cepheid
  • Leica Biosystems
  • Eiken Chemical
  • GenMark Diagnostics
  • Genotypic Technology Pvt. Ltd.
  • Grifols, S. A
  • Illumina
  • Immucor, Inc.
  • Meridian Bioscience Inc
  • Molbio Diagnostics Pvt. Ltd.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics